A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24108859 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Na He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China. Hauptthemen laut MEDLINE: Signal Transduction, Janus Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tao Jiang, Natural Science Foundation of China, Key Project of Greater Bay Area Institute of Precision Medicine (Guangzhou).
Abstract (Originalsprache)
The Janus kinase/signal transducer and activator of the transcription 3 (JAK/STAT3) signaling pathway controls multiple biological processes, including cell survival, proliferation, and differentiation. Abnormally activated STAT3 signaling promotes tumor cell growth, proliferation, and survival, as well as tumor invasion, angiogenesis, and immunosuppression. Hence, JAK/STAT3 signaling has been considered a promising target for antitumor therapy. In this study, a number of ageladine A derivative compounds were synthesized. The most effective of these was found to be compound 25. Our results indicated that compound 25 had the greatest inhibitory effect on the STAT3 luciferase gene reporter. Molecular docking results showed that compound 25 could dock into the STAT3 SH2 structural domain. Western blot assays demonstrated that compound 25 selectively inhibited the phosphorylation of STAT3 on the Tyr705 residue, thereby reducing STAT3 downstream gene expression without affecting the expression of the upstream proteins, p-STAT1 and p-STAT5. Compound 25 also suppressed the proliferation and migration of A549 and DU145 cells. Finally, in vivo research revealed that 10 mg/kg of compound 25 effectively inhibited the growth of A549 xenograft tumors with persistent STAT3 activation without causing significant weight loss. These results clearly indicate that compound 25 could be a potential antitumor agent by inhibiting STAT3 activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
- Innovation Platform of Marine Drug Screening & Evaluation, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266100, China.
- Laboratory for Marine Drugs and Bioproducts, Qingdao 266237, China.
ORCID-Profile: Li Li
Förderung
- Tao Jiang
- Natural Science Foundation of China
- Key Project of Greater Bay Area Institute of Precision Medicine (Guangzhou)
- Special Funds of Shandong Province for Qingdao National Laboratory of Marine Science and Technology
Zitieren
APA
He, N., Li, L., Li, R., Zhang, S. Q., Wu, L. H., Guan, X., Zhang, Q. Y., Jiang, T., & Yang, J. B. (2023). A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108859
Vancouver
He N, Li L, Li R, Zhang SQ, Wu LH, Guan X, et al. A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24108859
BibTeX
@article{He2023,
author = {He, Na and Li, Li and Li, Rui and Zhang, Si-Qi and Wu, Li-Hong and Guan, Xian and Zhang, Qian-Yue and Jiang, Tao and Yang, Jin-Bo},
title = {A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24108859}
}
EUVIMED